Table 4.
The effect of CKD on the molecular markers of left ventricular hypertrophy and fibrosis.
| Gene name | Gene symbol | log2 change | SD log2 change | p-value | Fold change |
|---|---|---|---|---|---|
| Natriuretic peptide A (ANP) | Nppa | 1.80 | 1.88 | 0.000 | 3.48* |
| Natriuretic peptide B (BNP) | Nppb | −0.55 | 1.63 | 0.118 | −1.46 |
| Myosin, Heavy Polypeptide 6, Cardiac Muscle, Alpha (α-MHC) | Myh6 | −1.26 | 1.34 | 0.000 | −2.39* |
| Myosin, Heavy Polypeptide 7, Cardiac Muscle, Beta (β-MHC) | Myh7 | −0.71 | 1.06 | 0.000 | −1.64 |
| Myocyte enhancer factor 2 C (predicted) | Mef2c | 0.23 | 0.25 | 0.000 | 1.17 |
| Myocyte enhancer factor 2D | Mef2d | 0.05 | 0.21 | 0.201 | 1.03 |
Gene expression ratios (CKD vs. control). Fold change of <−1.75 or >1.75 (repression or overexpression, respectively) and a p-value of <0.05 were considered as a significant change*, n = 6, unpaired t-test or Mann Whitney U test (Nppa, Nppb, and Mef2c).